Topic: Leukemia and Lymphoma

Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Nov 2024 | Assessment

Interventions of Interest Post-transplant lymphoproliferative disease (PTLD) is a rare, serious, often fatal complication of solid organ transplant (SOT) and allogeneic hematopoietic stem cell transplant (HCST), with only several hundred cases per year reported in the US. The majority of cases of PTLD are associated with the acquisition or reactivation of Epstein-Barr virus (EBV) post-transplant […]

Leukemia and Lymphoma

Mar 2018 | Assessment

Interventions of Interest: tisagenlecleucel (KymriahTM , Novartis) axicabtagene ciloleucel (YescartaTM, Kite Pharma) ICER developed a report on chimeric antigen receptor t-cell (CAR-T) therapies for treatment of B-cell malignancies. The policy recommendations highlight that even though the pricing of current CAR-T therapies aligns with patient benefit there will be changes needed in future pricing, payment, and […]